NEWSROOM

Healthcare

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Oct 18, 2024

NEWTOWN, Pa., Oct. 18, 2024 - PRISM MediaWire - Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

Oct 17, 2024

Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024

IRVINE, Calif., Oct. 16, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

Oct 15, 2024

Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Oct 15, 2024

KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Oct 15, 2024

Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...

In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

Oct 10, 2024

New York, New York, October 10, 2024 - PRISM MediaWire - PRISM MediaWire - Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition typically do not seek the proper help or treatment for fear of judgement or admission to being unstable. The reality of it is that whether or not you have a condition, we all need to do things to ensure we have good mental health in the...

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oct 8, 2024

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte Signs Leading Transplant Centers in US and Germany

Oct 2, 2024

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both...

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Oct 2, 2024

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Oct 1, 2024

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....

SS Innovations Welcomes Mr. Tim Adams, Leader in the Health Care Industry, to Board

SS Innovations Welcomes Mr. Tim Adams, Leader in the Health Care Industry, to Board

Sep 30, 2024

Tim Adams to serve as Independent Board Director FORT LAUDERDALE, FL, September 30, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, is pleased to announce the addition of Mr. Tim Adams to its Board of Directors, where he will serve as an Independent Director. Mr. Adams is a...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

Sep 30, 2024

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Sep 30, 2024

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...

Revolutionizing Surgery: SS Innovations International Inc. Celebrates 2,000 Procedures with its SSi Mantra Surgical Robotic System

Revolutionizing Surgery: SS Innovations International Inc. Celebrates 2,000 Procedures with its SSi Mantra Surgical Robotic System

Sep 23, 2024

Fort Lauderdale, FL., September 23, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, announced that it has now successfully completed over 2,000 robotic surgeries, primarily in India, using its SSi Mantra Surgical Robotic System (the “SSi Mantra”). The significance of the 2,000...

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

Sep 17, 2024

Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 - PRISM MediaWire - The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024

NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...

SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline

SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline

Sep 11, 2024

Fort Lauderdale, FL., September 11, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today issued an update on its progress and timeline in obtaining U.S. Food and Drug Administration (“FDA”) approvals to market the SSi Mantra Surgical Robotic System (“SSi Mantra”) in the United...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Sep 11, 2024

Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology...

SS Innovations Welcomes “Father of Surgical Robotics” Dr. Fredric Moll to Board

SS Innovations Welcomes “Father of Surgical Robotics” Dr. Fredric Moll to Board

Sep 10, 2024

Dr. Moll, founder of Intuitive Surgical, to serve as Vice Chairman FORT LAUDERDALE, FL, September 10, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, is pleased to announce the addition of Dr. Fredric Moll to its Board of Directors, where he will serve as Vice Chairman. Dr. Moll is...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 9, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Added to PRISM Emerging Medical Devices Index

Sep 6, 2024

Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Sep 4, 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...

SS Innovations Welcomes “Father of Surgical Robotics” Dr. Fredric Moll to Board

SS Innovations International, Inc. Announces First Mantra Surgical Robotic System Sale in South America

Sep 3, 2024

SS Innovations receives Regulatory Approval for Clinical Use in Ecuador SS Innovations Partners with Medical Device Firm Ingemedica S.A. for Distribution in Ecuador The first SSi Mantra Surgical Robotic System to be installed at Interhospital, Guayaquil City, Ecuador Fort Lauderdale, FL., September 3, 2024 - SS Innovations International, Inc. (the Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery...

SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock

SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock

Aug 30, 2024

Fort Lauderdale, FL., August 30, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today issued an update to its shareholders and the investment community on the status of its audit process and the trading market for its common stock. As previously reported in its Securities and Exchange...

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Aug 29, 2024

Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9th through 11th in New York City at the Lotte Palace Hotel....

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 27, 2024

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...